

IMMUNOHISTOCHEMISTRY

Client Services

Brentwood, TN: (800) 874-8532 fax: (615) 370-8074 Phoenix, AZ: (800) 710-1800 fax: (800) 481-4151 Shelton, CT: (800) 447-5816 fax: (212) 698-9532

Highlighted fields are REQUIRED

ORDERING PHYSICIAN				(CLINICAL/S	PECIMEN INFOR	MATION	
PHYSICIAN		N	PI#		Collection Date:		Time:	Fixative: 10% Neutral Buffered Formalin
					Body Site/Descriptor:			Other:
TREATING PHYSICIAN		N	PI#	ç	Specimen ID#(s):			See Previous Case History
				<u>[</u>	Paraffin Block(s) #:	Choose best block (default)	Stained Slides #:	Unstained Slides #: Other:
Client#						Perform tests on all block	(S	
Client Name					Diagnosis/Clinical Da	ta:		
				-				
Address				7	All diagnoses should b	be provided by the ordering phy	reician or an author	rizad decignee
				Ĺ	Diagnosis/Signs/Symp	ptoms in ICD-CM format in effe	ect at Date of Servic	ce (Highest Specificity Required)
					ICD-CM	ICD-CM		ICD-CM
Phone Number				1				ick of insurance card must be attached)
Phone Number					Bill: My Account Insurance Medicare Medicaid Patient Workers Comp See attached			
Fax Number					Patient Hospital Status: Inpatient Outpatient Non-Patient			
PATIENT INFORMATION					Insured Information	n: Name		
Name (LAST, FIRST, MIDDLE):					Relationship to Pat	ient (circle one) Self S	pouse Child	Other:
Address:				F	Primary Insurance Co: Authorization #			
					Billing Address			Insured #
City, State, Zip:	/ DD / YYYY	0			Billing City, State, Z	Zip		Group #
	I/DD/TITT	Sex:		F 5	Secondary Insuran	ce Co: G	roup #	Insured #
Phone Number:								
Med Rec # / Patient #: PHYSICIAN/AUTHORIZED SIGNATURE: SELECT A LEVEL OF SERVICE (MUST CHOOSE ONE) - INCLUDE SURGICAL PATHOLOGY REPORT								
			MUST C	CHOOSE ON	NE) - INCLUI	DE SURGICAL PA	THOLOG	Y REPORT
	Technical Componen		anh		□ IHC Stain	with Manual Interp	retation	
	vith Virtual Image - Te	chnical Component	oniy					
Actin - Muscle Sp Actin - Smooth M Adipophilin At1/AE3 (pan-cyt) AE1/AE3/PCK26 (AFB AFP (Alpha Fetop) ALK (D5F3 for NS ALK-1 Amyloid A Androgen Receptt Androgen Recept	uscle (SMA)	(LCA, Leukocyte Common Ant	□ F □ G iigen) □ G □ G □ G □ G □ G	OLR1 SH (Follicular Stimu Salectin-3 Gastrin GATA-3 GCDFP-15 SFAP (Glial Fibrillary Slycophorin A	ulating Hormone)	Mammaglobin MART-10 MDM2 Melan-A Melan-A/Ki-67 (Double S Mesothelin MITF MITF-1	tain)	 Pneumocystis carinii (PC) PR (Progesterone Receptor) PRAME Prolactin PSA (Prostate Specific Antigen) PSAP (Prostatic Acid Phosphatase)
Arginase-1 Arginase-1 B72.3 (TAG72) BCL-1 (Cyclin D1) BCL-2 BCL-2/BCL-6@ BCL-6 Ber-EP4 (Epithelia Beta-Amyloid Beta-Catenin BOB-1 BRAF V600E CA 19.9 CA 12.5 CAIX (Carbonic Al Calcitonin Calconin Colda CD3 CD3 CD3 CD5 CD7 CD8 CD10 CD14 CD15 CD20 CD21	□ C099 □ CD117 □ CD138 □ CD138 □ CD138 □ CD138 □ CD138 □ CD138 □ CD138 □ CD142 □ CDX-2 □ CDX-2 □ CDX-2 □ CDX-2 □ CDX-2 □ CAX-4 □ CAX-4 □ CK-5% □ CK-5% □ CK-5% □ CK-5% □ CK-5% □ CK-5% □ CK-4 □ CK-17 □ CK-18 □ CK-17 □ CK-18 □ CK-17 □ CK-18 □ CK-20 □ CK-40 □ CK-10 □ CK-20 □ CK-40 □ CK-20 □ CC-20 □ CC-20	(c-KIT) /CK-7 Aonoclonal) Yolyclonal) ogranin A trypsin TF-1 W (34betaE12) W (35betaH11) n 18 Cytomegalovirus) IV (Type 4 Collagen) Red I (HCL) n Sy ISH	0000111111 ET	Silypican-3 SMS Sranzyme B Growth Hormone (Gi HBME-1 (Human Me GG (Human Chorio Hemoglobin A HEP PAR 1 HER2 - Global breast 1 esults (2+) with be refit HER2 - Global gastric esults (2+) with be refit HER2 - Global gastric HALS (Herpes Virus LA-DR HMB-45 HPL (Human Placent HPV 16/18 by ISH 1- pylori (HBP) SV /HSV II (Herpes GA gG gG4*	H) esothelial Cell) nic Gonadotropin) IHC with equivocal eflexed to FISH IHC with equivocal FISH reflex) Type 8) tal Lactogen) Simplex Virus I & II)	 MOC-31 (Epithelial Relat MPO (Myeloperoxidase) MSH-6 MUC1 MUC2 MUC4 MUC5AC MUW-1 (Multiple Myelor Myogenin Myogiobin Myosin Heavy Chain (SM Napsin A Neurofilament (NF) NKI-C3 (Meuron Specific En OCT-2 OCT-3/4 OSCAR[®] p16 p53 p57 o63 	na Oncogene 1) IM-HC) c. Antigen) olase) 3/PCK26) [MART-1, [©] (semi-quant) [™] (semi-quant)	 □ PSMA@ □ PTH (Parathyroid Hormone) □ RCC (PNRA, Renal Cell Carcinoma) □ S100 □ SALL4 □ S0X11 □ STAT6 □ SAT82 □ Synaptophysin (Monoclonal) □ Synuclein@ □ TCL-1 □ TDT □ Thrombomodulin □ Thyroglobulin □ TIA-1 □ TLE1 □ TOX0 (Toxoplasmosis) □ TRAP □ TriView Breast Triple Stain (CK-5/6, p63, CK-LMW) (Breast Microinvasion)@ □ TriView Prostate Triple Stain (P504S, p63, CK903) Tech only □ Tryptase M-Cell □ TSH (Thyroid Stimulating Hormone) □ TTF-1 (Thyroid Transcription Factor 1) □ Tyrosinase □ Uroplakin III □ Villin □ Winentin (VIM) □ WT-1 (N-Terminus)

© 2024 Laboratory Corporation of America® Holdings. All rights reserved.

*For manual interp, must be ordered with IgG

Determining Necessity of Advance Beneficiary Notice of Non-coverage (ABN) Completion*

- 1. Diagnose. Determine your patient's diagnosis.
- 2. Document. Write the diagnosis code(s) on the front of this requisition.
- 3. Verify. Determine if the laboratory test(s) ordered for the patient is subject to Local Coverage Determination or National Coverage Determination. This information can be located in the policies published by your Medicare Administrative Contractor (MAC), CMS, or www.Labcorp.com/MedicareMedicalNecessity.
- 4. Review. If the diagnosis code for your patient does not meet the medical necessity requirements set forth by Medicare or the test(s) is being performed more frequently than Medicare allows, an ABN should be completed.
- *An ABN should be completed for all tests that are considered investigational (experimental or for research use) by Medicare.

How to Complete an Advance Beneficiary Notice of Non-coverage (ABN)

Medicare is very specific in requiring that all of the information included on the ABN be completed. Additionally, Labcorp requests that the specimen number or bar code label be included on the form. To be valid an ABN must:

- Be executed on the CMS approved ABN form (CMS-R-131) 1
- Identify the Medicare Part B Beneficiary, using the name as it appears on the patient's red, white and blue Medicare card 2.
- 3. Indicate the test(s)/procedure(s) which may be denied within the relevant reason column
- 4. Include an estimated cost for the test(s)/procedure(s) subject to the ABN
- 5. Have 'Option 1', 'Option 2', or 'Option 3' designated by the beneficiary
- 6. Be signed **and** dated by the beneficiary or his/her representative **prior to** the service being rendered

When ordering tests for which Medicare or Medicaid reimbursements will be sought, physicians should order only those tests that are medically necessary for the diagnosis or treatment of the patient.

Patient, Client and Billing Information is requested for timely processing of this case. Medicare and other third party payors require that services be medically necessary for coverage, and generally do not cover routine screening tests.

Refer to Determining Necessity of ABN Completion on reverse.

- Performed in Shelton, CT only
 Performed in Phoenix, AZ and Brentwood, TN only
 Performed in Phoenix, AZ only
- ④ Performed in Brentwood, TN only

NOTE: The most updated antibody library is available at oncology.labcorp.com